Immuneering Corporation (NASDAQ:IMRX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Immuneering Corporation has received a consensus rating of "Moderate Buy" from five analysts, with one sell and four buy ratings, and an average target price of $13.25.
• Insiders, including Director Peter Feinberg and CEO Benjamin J. Zeskind, have recently increased their holdings, with Feinberg purchasing 25,000 shares and Zeskind acquiring 21,000 shares.
• The stock opened at $3.25, with a one-year low of $1.00 and a high of $4.69, while currently 67.65% of shares are held by institutional investors.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $13.25.

IMRX has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and set a $9.00 price objective on shares of Immuneering in a research report on Wednesday, June 18th. Mizuho upped their price objective on Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Wednesday, June 18th. Oppenheimer decreased their price objective on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and set a $13.00 price objective on shares of Immuneering in a research report on Wednesday, June 18th.

Immuneering Price Performance

Shares of IMRX stock opened at $3.25 on Friday. Immuneering has a 1 year low of $1.00 and a 1 year high of $4.69. The stock's 50 day simple moving average is $3.26 and its two-hundred day simple moving average is $2.15. The company has a market cap of $116.97 million, a PE ratio of -1.66 and a beta of 0.37.

Insider Transactions at Immuneering

In other Immuneering news, Director Peter Feinberg purchased 25,000 shares of Immuneering stock in a transaction dated Wednesday, June 18th. The shares were purchased at an average cost of $2.53 per share, for a total transaction of $63,250.00. Following the completion of the acquisition, the director owned 136,766 shares in the company, valued at $346,017.98. This represents a 22.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Benjamin J. Zeskind purchased 21,000 shares of Immuneering stock in a transaction dated Wednesday, June 18th. The stock was acquired at an average price of $2.39 per share, for a total transaction of $50,190.00. Following the completion of the acquisition, the chief executive officer owned 2,302,852 shares of the company's stock, valued at approximately $5,503,816.28. This trade represents a 0.92% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 127,507 shares of company stock worth $334,318. 22.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new position in Immuneering during the 4th quarter worth $47,000. Two Sigma Investments LP increased its holdings in Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after purchasing an additional 10,126 shares during the period. Rockefeller Capital Management L.P. purchased a new position in Immuneering during the 4th quarter worth $390,000. Bridgeway Capital Management LLC boosted its position in Immuneering by 77.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after acquiring an additional 22,400 shares in the last quarter. Finally, First Manhattan CO. LLC. bought a new stake in Immuneering during the 4th quarter valued at $71,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.